The role of intravenous iron in anemia management and transfusion avoidance. (se deschide o fereastră nouă)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Sursă‎: Transfusion 2008;48(5):988-1000.

Index‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (se deschide o fereastră nouă)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (se deschide o fereastră nouă)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Sursă‎: BJU Int 2011;108(10):1582-7.

Index‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (se deschide o fereastră nouă)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (se deschide o fereastră nouă)

Lepor H, Lipkin M, Slova D.

Sursă‎: Urology 2010;75(6):1424-8.

Index‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (se deschide o fereastră nouă)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (se deschide o fereastră nouă)

Nieder AM, Rosenblum N, Lepor H.

Sursă‎: Urology 2001;57(4):737-41.

Index‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (se deschide o fereastră nouă)